Amedisys (AMED) Tops Q4 EPS by 5c

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $337.3 million versus the consensus estimate of $322.01 million.

Earnings before interest, taxes, depreciation and amortization attributable to continuing operations (“EBITDA”) of $27.6 million compared to $22.9 million in 2014.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• Columbus McKinnon names John Linker as CFO, reaffirms FY2027 guidance